JP Morgan Chase
NKTR icon

JP Morgan Chase’s Nektar Therapeutics NKTR Stock Holding History

JP Morgan Chase’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7
Closed -$1K – 6741
2022
Q1 		$1K Sell
7
-3,580
-100% -$530K ﹤0.01% 6487
2021
Q4 		$727K Buy
3,587
+767
+27% +$166K ﹤0.01% 4601
2021
Q3 		$760K Hold
2,820
– – ﹤0.01% 4489
2021
Q2 		$726K Hold
2,820
– – ﹤0.01% 4488
2021
Q1 		$846K Buy
+2,820
New +$878K ﹤0.01% 4348
2019
Q4 		– Sell
-1,253
Closed -$342K – 5792
2019
Q3 		$342K Hold
1,253
– – ﹤0.01% 4357
2019
Q2 		$652K Sell
1,253
-2,067
-62% -$1.04M ﹤0.01% 4103
2019
Q1 		$1.67M Buy
3,320
+653
+24% +$387K ﹤0.01% 3456
2018
Q4 		$1.31M Buy
+2,667
New +$1.61M ﹤0.01% 3568
2018
Q3 		– Sell
-94,040
Closed -$68.9M – 5762
2018
Q2 		$68.9M Buy
+94,040
New +$108M 0.01% 819
2018
Q1 		– Sell
-3,800
Closed -$3.4M – 5545
2017
Q4 		$3.4M Buy
+3,800
New +$2.25M ﹤0.01% 2979

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's NKTR Position: Q2 2026 in Review

JP Morgan Chase reduced its Nektar Therapeutics (NKTR) stake by 91% in Q2 2026, selling an estimated $15.9M and leaving 22,138 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #4388.

JP Morgan Chase first reported a position in NKTR in Q2 2013 and has held it in 53 quarters since. The position peaked at $135M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • JP Morgan Chase held 22,138 shares of Nektar Therapeutics worth $1.54M as of Q2 2026.
  • JP Morgan Chase sold 217,964 Nektar Therapeutics shares in Q2 2026, an estimated $15.9M.
  • Nektar Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4388 holding.
  • JP Morgan Chase first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Nektar Therapeutics position peaked at $135M in Q1 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.